Patient-reported outcomes with botulinum neurotoxin type A

Area of Science:

• Aesthetic Medicine
• Dermatology
• Ophthalmology

Background:

• Traditional clinical trials for botulinum neurotoxin type A (e.g., BOTOX Cosmetic) relied on investigator and global patient assessments.
• These traditional outcomes have limited value in reflecting patient-desired benefits for facial rejuvenation.

Purpose of the Study:

• To evaluate the utility of patient-reported outcome measures (PROMs) in assessing the efficacy of botulinum neurotoxin type A for facial aesthetics.
• To highlight the importance of PROMs in understanding patient motivations and satisfaction in aesthetic treatments.

Main Methods:

• Utilized patient-reported outcome measures, including the Self-Perception of Age (SPA) measure and the Facial Line Outcomes (FLO) questionnaire.
• Analyzed data from clinical trials involving botulinum neurotoxin type A for upper facial lines and glabellar treatment.

Main Results:

• Clinical trials demonstrated significant improvements in SPA and FLO outcomes from baseline and compared to placebo.
• The Facial Line Outcomes (FLO) questionnaire assesses patient concerns regarding facial lines, perceived age, smoothness, and expressions (tired, stressed, angry).

Conclusions:

• Patient-reported outcomes provide valuable insights into patient objectives and satisfaction with facial rejuvenation treatments.
• PROMs like SPA and FLO enhance treatment planning and help clinicians demonstrate treatment value to patients.